TY  - GEN
AU  - Manns,Michael
AU  - Marcellin,Patrick
AU  - Poordad,Fred
AU  - de Araujo,Evaldo Stanislau Affonso
AU  - Buti,Maria
AU  - Horsmans,Yves
AU  - Janczewska,Ewa
AU  - Villamil,Federico
AU  - Scott,Jane
AU  - Peeters,Monika
AU  - Lenz,Oliver
AU  - Ouwerkerk-Mahadevan,Sivi
AU  - De La Rosa,Guy
AU  - Kalmeijer,Ronald
AU  - Sinha,Rekha
AU  - Beumont-Mauviel,Maria
TI  - Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
SN  - 1474-547X
PY  - 2014///0818
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Antiviral Agents
KW  - administration & dosage
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - Drug Therapy, Combination
KW  - Female
KW  - Genotype
KW  - Hepacivirus
KW  - genetics
KW  - Hepatitis C, Chronic
KW  - drug therapy
KW  - Heterocyclic Compounds, 3-Ring
KW  - Humans
KW  - Interferon alpha-2
KW  - Interferon-alpha
KW  - Male
KW  - Middle Aged
KW  - Polyethylene Glycols
KW  - Recombinant Proteins
KW  - Ribavirin
KW  - Simeprevir
KW  - Sulfonamides
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S0140-6736(14)60538-9
ER  -